In This Article:
LYON, France, May 21, 2025--(BUSINESS WIRE)--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 11th, 2025, at 2:00 pm, in the Jones Day’s offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris.
The notice of this shareholders’ meeting, which serves as the convening notice was published on May 7th, 2025, in the French Bulletin des Annonces Légales Obligatoires ("BALO"). It includes the agenda, the proposed resolutions and instructions for participating and voting at this meeting.
In accordance with the regulations in force, all documentation concerning the meeting is available to shareholders on the company's website: https://www.adocia.com/investors/general-meeting/
Precisions regarding the AGM
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight (Paris time), will be able to participate physically in the AGM. Shareholders holding bearer shares ("actions au porteur") will need to obtain a certificate of shareholding ("attestation de participation") from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person.
Shareholders must submit written questions no later than the fourth business day prior to the AGM. Questions can be sent by registered mail to the company's registered office or by email to the following address: ag2025@adocia.com. In order to be considered, questions must be accompanied by an "attestation de participation".
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.